Skip to content

Advertisement

  • Poster presentation
  • Open Access

The kinetics of HTLV-1 proviral load after allogeneic hematopoietic cell transplantation with reduced intensity conditioning regimen; a comparison with that from sibling donors and that from unrelated donors

  • 1,
  • 2,
  • 3,
  • 1,
  • 4 and
  • 1
Retrovirology201411 (Suppl 1) :P19

https://doi.org/10.1186/1742-4690-11-S1-P19

  • Published:

Keywords

  • Elderly Patient
  • Virus Type
  • Conditioning Regimen
  • Undetectable Level
  • Unrelated Donor

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy that is caused by human T-lymphotropic virus type 1 (HTLV-1) with poor prognosis. We have reported the feasibility and efficacy of allogeneic hematopoietic cell transplantation with reduced intensity conditioning (RIC-HCT) for elderly patients with ATL, and have also shown that in more than half of patients the HTLV-1 proviral load (HTLV-PL) decreased to an undetectable level after RIC-SCT, suggested presence of anti HTLV-1 effects. In this study, we try to compare the kinetics of HTLV-PL after RIC-SCT from HTLV-1 antibody negative sibling donor (SD) with that from unrelated donors (UD), all of whom were HTLV-1 antibody negative. Fourteen patients were included in the SD group, and fifteen patients were in UD group. The HTLV-PL decreased to an undetectable revel in 11 of 14 patients (78.6%) in the SD group and 13 of 15 (86.7%) in the UD group with in 120 days after RIC-SCT. In short term, the kinetics of the HTLV-PL after RIC-SCT from UD was almost similar to that from HTLV-1 negative SD. Looking at the long term follow-up results, the HTLV-PL remains to be an undetectable level in only 2 of 11 (18.2%) patients in the SD group (median follow up 111 months [101-122])), on the other hand, 7 of 13 (53.8%) patient in the UD group (24 month [20-36]). RIC-HCT from UD tends to have better anti-HTLV-1 effect, compared with that from SD, but not conclusive because of the short follow-up period.

Authors’ Affiliations

(1)
Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan
(2)
Clinical Laboratories Division, National Cancer Center Hospital, Tokyo, Japan
(3)
Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
(4)
Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan

Copyright

Advertisement